News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Euro News, Articles and Videos with Contenting
1. "EU Proposes New Rules on Digital Tax to Make Tech Giants Pay Their Share" - This article from Reuters discusses how the European Union's executive branch proposed new rules for digital taxation to ensure tech giants pay their fair share of taxes. The new rules are set to impact companies like Amazon, Apple, Facebook, and Google. 2. "Germany, France and Italy Sign Pact to Tax Digital Giants" - This article from the New York Times discusses how Germany, France, and Italy have signed a pact to tax digital companies such as Amazon, Apple, Facebook, and Google. The agreement is the first major step in the European Union's effort to tax tech giants. 3. "EU's New Digital Tax Plan: What You Need to Know" - This video from Euronews explains the European Union's new digital tax plan and how it will affect tech giants such as Amazon, Apple, Facebook, and Google. The video also explains the different aspects of the plan and how it will be implemented.
Disposal of shares in Trigon Property Development AS - ForexTV
Nordic Fibreboard AS subsidiary Nordic Fibreboard Ltd OÜ owned 17.88% (804,552 shares) of the listed company AS Trigon Property Development. On February 21 2025, Nordic Fibreboard Ltd OÜ entered into a sales agreement, by which Nordic Fibreboard Ltd OÜ will sell its shares in AS Trigon Property Development to Trigon Carbon Negative Agriculture OÜ. Nordic Fibreboard Ltd OÜ will sell the shares at the closing price on 19.02.2025, i.e 0.67 euros per share (total amount 539,049.84 euros). The participation in TPD was not significant for the main activities of Nordic Fibreboard Ltd OÜ and the transaction does not have a significant impact on the profit, assets and liabilities of Nordic Fibreboard Ltd OÜ. According to the rules established for the issuer by the NASDAQ Tallinn Stock Exchange, the aforementioned sale transaction must be treated as a transaction with a related party. Joakim Johan Helenius owns directly and indirectly 68.86% of Nordic Fibreboard AS shares and indirectly 100% of Trigon Carbon Negative Agriculture OÜ shares. The transaction has been completed on market terms. The members of the supervisory board and management board of Nordic Fibreboard AS have no other personal interest in the transaction. AS Trigon Property Development and Nordic Fibreboard AS have no valid agreements between them. Enel Äkke Member of the Management BoardNordic Fibreboard ASgroup@nordicfibreboard.com
The Rise of Quantum Key Distribution Market: A $2.63 billion Industry Dominated by Tech Giants - Toshiba (Japan) and MagiQ Technologies (US)| MarketsandMarkets™ - ForexTV
Delray Beach, FL, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The global Quantum Key Distribution Market size is projected to grow from USD 0.48 billion in 2024 to USD 2.63 billion by 2030 at a Compound Annual Growth Rate (CAGR) of 32.6% during the forecast period, according to a new report by MarketsandMarkets™. The demand for Quantum Key Distribution (QKD) is growing as organizations seek to strengthen data security. With cyberattacks becoming more advanced, companies and governments face significant challenges in protecting sensitive information. Additionally, there are increasing developments in the QKD space. For instance, TIM Group companies Sparkle and Telsy, along with QTI Quantum Telecommunications Italy, successfully performed a Proof of Concept (PoC) to secure a high-capacity link with QKD between two data centers in Athens, further driving the growth of the QKD market. Browse in-depth TOC on "Quantum Key Distribution Market" 515 - Tables 59 - Figures 342 - Pages Download Report Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80654677 Quantum Key Distribution Market Dynamics: Drivers: Rise in ‘harvest now, decrypt later’ (HNDL) attacksIncrease in investments in R&D by prominent playersAdvancements in quantum communication infrastructureAdvancements in quantum computing Restraints: High implementation costsLack of standardization Opportunities: Expansion into 5G, IoT networks, and satellite-based quantum communicationRise in demand for data security List of Key Companies in Quantum Key Distribution Market: Toshiba (Japan)ID Quantique (Switzerland)QuintessenceLabs (Australia)MagiQ Technologies (US)QuantumCTek (China)LuxQuanta (Spain)Kloch (US)HEQA Security (Israel)QNu Labs (India)PacketLight Networks (Israel) Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=80654677 Trend: Advancements in Satellite-based QKD Satellite networks are saturating themselves with quantum technologies, aiming to carry out secure data transmission at long range. The drive behind this trend is a secure communication need across the globe's infrastructures, largely now spearheaded by projects like European Space Agency quantum initiatives. In India, for example, in January 2022, scientists from the Space Applications Centre (SAC) and the Physical Research Laboratory (PRL) demonstrated real-time Quantum Key Distribution (QKD) over a 300m terrestrial channel incorporating both quantum-secure text and image transmission and a quantum-assisted two-way video call between two buildings. By type, the long-distance QKD system segment accounts for the highest CAGR during the forecast period. The long-distance QKD system segment is projected to experience the highest Compound Annual Growth Rate (CAGR) during the forecast period. This growth is driven by the increasing need for secure communication across vast distances, particularly in sectors like defense, government, and telecommunications. As organizations seek to protect critical data transmissions over extended networks, advancements in satellite-based and fiber-optic QKD systems are gaining momentum, further propelling the demand for long-distance QKD solutions. Additionally, ongoing research and development efforts are enhancing the feasibility and scalability of these systems, contributing to their rapid adoption. Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=80654677 By vertical, the BFSI vertical accounts for a larger market share. The BFSI segment is expected to hold larger market share during the forecast period. This is led by the the sector’s critical need for enhanced data security. The BFSI industry is one of the most data-sensitive sectors, managing vast amounts of confidential information, including customer identities, financial transactions, and proprietary business data. With the rising frequency and sophistication of cyberattacks targeting financial institutions, there is an increasing demand for robust encryption methods to safeguard this valuable data. QKD's ability to provide theoretically unbreakable encryption by detecting eavesdropping in real time makes it an ideal solution for the BFSI sector. Financial institutions are adopting QKD to ensure secure communication and to prevent data breaches, fraud, and identity theft. Additionally, regulatory pressures related to data privacy, such as the General Data Protection Regulation (GDPR) in Europe and other global financial compliance standards, are encouraging the implementation of more advanced security measures like QKD. Opportunity: Securing 5G Networks with Quantum Key Distribution (QKD) One major opportunity in Quantum Key Distribution (QKD) lies in its application for securing 5G and beyond networks. As global 5G deployment accelerates, the need for stronger encryption mechanisms to protect massive volumes of data transmitted across these networks becomes critical. QKD offers an unbreakable key exchange, which can ensure secure communication in industries such as telecommunications, healthcare, and autonomous vehicles. The integration of QKD into 5G infrastructure could provide future-proof security against both current cyber threats and potential quantum computer attacks, opening new avenues for partnerships and technology investments. Get access to the latest updates on Quantum Key Distribution Companies and Quantum Key Distribution Industry CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets Inc. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA : 1-888-600-6441 UK +44-800-368-9399 Email: sales@marketsandmarkets.com Visit Our Website: https://www.marketsandmarkets.com/
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - ForexTV
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million, representing year-over-year growth of 47% The U.S. Food and Drug Administration (FDA) accepted for review the lumateperone supplemental New Drug Application (sNDA) submission for adjunctive treatment of major depressive disorder (MDD) BEDMINSTER, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter ended December 31, 2024 and provided a corporate update. Financial Highlights Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023. Net product sales of CAPLYTA were $199.2 million for the fourth quarter of 2024, compared to $131.5 million for the same period in 2023, representing 51% growth. Selling, general and administrative (SG&A) expenses were $504.5 million for the year ended December 31, 2024, compared to $409.9 million for the same period in 2023. This increase is primarily due to an increase in commercialization, marketing and infrastructure costs. Research and development (R&D) expenses were $236.1 million for the year ended December 31, 2024, compared to $180.1 million for the same period in 2023. This increase is primarily due to higher lumateperone and non-lumateperone project costs, including the ITI-1284, ITI-214, and ITI-1500 programs. Cash, cash equivalents, investment securities, and restricted cash totaled $1.0 billion on December 31, 2024, compared to $499.7 million at December 31, 2023. Commercial and Clinical Highlights In the first quarter of 2025, we commenced a field sales force expansion in anticipation of the potential approval of CAPLYTA for the adjunctive treatment of MDD. The FDA has accepted for review the sNDA for lumateperone, an investigational agent for the treatment of MDD as adjunctive therapy. Two positive Phase 3 global placebo-controlled studies, Study 501 and Study 502, as well as the long term open-label safety Study 503, form the basis of the sNDA. Advancing our pipeline: In 2024, we initiated 10 late-stage clinical trials including six Phase 3 lumateperone clinical trials and four ITI-1284 clinical trials.Lumateperone: In our pediatric program, in the fourth quarter of 2024, we commenced patient enrollment in two Phase 3 studies in pediatric patients for the treatment of irritability associated with autism spectrum disorder. Patient enrollment is ongoing in our double-blind, placebo-controlled study in bipolar depression and in our open-label safety study in schizophrenia and bipolar disorder in pediatric patients.Patient enrollment is ongoing in our two Phase 3 studies evaluating lumateperone in adults in the acute treatment of manic or mixed episodes associated with bipolar I disorder (bipolar mania). ITI-1284-ODT-SL program: Patient enrollment is ongoing in two Phase 2 clinical studies evaluating ITI-1284 in patients with generalized anxiety disorder (GAD). Our first study evaluates ITI-1284 as an adjunctive therapy to approved GAD medications while a second study evaluates ITI-1284 as monotherapy.Patient enrollment continues in a Phase 2 clinical study evaluating ITI-1284 in patients with psychosis associated with Alzheimer’s disease (AD) and in our Phase 2 program in agitation associated with AD. Other pipeline programs:Phosphodiesterase type I inhibitor (PDE1) program: Patient enrollment in our lenrispodun (ITI-214) Phase 2 Study in Parkinson’s disease (PD) is ongoing. Our second PDE1 inhibitor, ITI-1020 being developed in oncology indications, continues its Phase 1 single ascending dose study in healthy volunteers.ITI-1500 non-hallucinogenic neuroplastogen program: ITI-1549 is advancing IND enabling studies. Important Safety Information Boxed Warnings: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. All antidepressant-treated patients should be closely monitored for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA have not been established in pediatric patients. Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA. Reactions have included pruritus, rash (e.g., allergic dermatitis, papular rash, and generalized rash), and urticaria. Warnings & Precautions: Antipsychotic drugs have been reported to cause: Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis, including stroke and transient ischemic attack. See Boxed Warning above.Neuroleptic Malignant Syndrome (NMS), which is a potentially fatal reaction. Signs and symptoms include: high fever, stiff muscles, confusion, changes in breathing, heart rate, and blood pressure, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Patients who experience signs and symptoms of NMS should immediately contact their doctor or go to the emergency room.Tardive Dyskinesia, a syndrome of uncontrolled body movements in the face, tongue, or other body parts, which may increase with duration of treatment and total cumulative dose. TD may not go away, even if CAPLYTA is discontinued. It can also occur after CAPLYTA is discontinued.Metabolic Changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA and monitor periodically during long-term treatment.Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases). Complete blood counts should be performed in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. CAPLYTA should be discontinued if clinically significant decline in WBC occurs in absence of other causative factors.Decreased Blood Pressure & Dizziness. Patients may feel lightheaded, dizzy or faint when they rise too quickly from a sitting or lying position (orthostatic hypotension). Heart rate and blood pressure should be monitored and patients should be warned with known cardiovascular or cerebrovascular disease. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension.Falls. CAPLYTA may cause sleepiness or dizziness and can slow thinking and motor skills, which may lead to falls and, consequently, fractures and other injuries. Patients should be assessed for risk when using CAPLYTA.Seizures. CAPLYTA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold.Potential for Cognitive and Motor Impairment. Patients should use caution when operating machinery or motor vehicles until they know how CAPLYTA affects them.Body Temperature Dysregulation. CAPLYTA should be used with caution in patients who may experience conditions that may increase core body temperature such as strenuous exercise, extreme heat, dehydration, or concomitant anticholinergics.Dysphagia. CAPLYTA should be used with caution in patients at risk for aspiration. Drug Interactions: CAPLYTA should not be used with CYP3A4 inducers. Dose reduction is recommended for concomitant use with strong CYP3A4 inhibitors or moderate CYP3A4 inhibitors. Special Populations: Newborn infants exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Dose reduction is recommended for patients with moderate or severe hepatic impairment. Adverse Reactions: The most common adverse reactions in clinical trials with CAPLYTA vs. placebo were somnolence/sedation, dizziness, nausea, and dry mouth. CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules. Please click here to see full Prescribing Information including Boxed Warning. About CAPLYTA (lumateperone) CAPLYTA 42 mg is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. While the mechanism of action of CAPLYTA is unknown, the efficacy of CAPLYTA could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. Lumateperone is being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Lumateperone is not FDA-approved for these disorders. About Intra-Cellular Therapies Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com. Forward-Looking Statements This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the potential approval of CAPLYTA (lumateperone) for the treatment of major depressive disorder as adjunctive therapy; our financial and operating performance, including our future revenues and expenses; our expectations regarding the commercialization of CAPLYTA; our plans to expand our sales force; our plans to conduct clinical or non-clinical trials and the timing of developments with respect to those trials, including enrollment, initiation or completion of clinical conduct, or the availability or reporting of results; whether clinical trial results will be predictive of future real-world results; whether CAPLYTA will serve an unmet need; the goals of our development programs; our beliefs about the potential utility of our product candidates; and development efforts and plans under the caption “About Intra-Cellular Therapies.” All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the following: there is no guarantee we will complete the pending transaction with Johnson & Johnson within the timeframe we anticipate or at all; there are no guarantees that CAPLYTA will be commercially successful; we may encounter issues, delays or other challenges in commercializing CAPLYTA; whether CAPLYTA receives adequate reimbursement from third-party payors; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indications; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results achieved in CAPLYTA in the treatment of schizophrenia and bipolar depression following commercial launch of the product may be different than observed in clinical trials, and may vary among patients; challenges associated with supply and manufacturing activities, which in each case could limit our sales and the availability of our product; risks associated with our current and planned clinical trials; we may encounter unexpected safety or tolerability issues with CAPLYTA following commercial launch for the treatment of schizophrenia or bipolar depression or in ongoing or future trials and other development activities; there is no guarantee that a generic equivalent of CAPLYTA will not be approved and enter the market before the expiration of our patents; there is no guarantee that our sNDA for the adjunctive treatment of MDD will be approved, if at all, on the timeline that we expect; our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials or in clinical trials for other indications; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development of our product candidates; impacts on our business, including on the commercialization of CAPLYTA and our clinical trials, as a result of the COVID-19 pandemic, the conflicts in Ukraine, Russia and the Middle East, global economic uncertainty, inflation, higher interest rates or market disruptions; and the other risk factors detailed in our public filings with the Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law. Contact: Intra-Cellular Therapies, Inc.Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations646-440-9333 Burns McClellan, Inc.Cameron Radinoviccradinovic@burnsmc.com212-213-0006 INTRA-CELLULAR THERAPIES, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands except share and per share amounts) (Unaudited) (1)(2) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Revenues Product sales, net$199,223 $131,507 $680,501 $462,175 Grant revenue — 593 351 2,195 Total revenues, net 199,223 132,100 680,852 464,370 Operating expenses: Cost of product sales 20,405 10,703 56,963 33,745 Selling, general and administrative 137,729 104,720 504,489 409,864 Research and development 70,286 50,773 236,121 180,142 Total operating expenses 228,420 166,196 797,573 623,751 Loss from operations (29,197) (34,096) (116,721) (159,381)Interest income 11,995 6,242 42,518 20,343 Loss before provision for income taxes (17,202) (27,854) (74,203) (139,038)Income tax expense 317 (450) (473) (636)Net loss$(16,885) $(28,304) $(74,676) $(139,674)Net loss per common share: Basic & Diluted$(0.16) $(0.29) $(0.72) $(1.46)Weighted average number of common shares: Basic & Diluted 106,095,836 96,285,558 103,131,017 95,881,729 (1) The condensed consolidated statements of operations for the three and twelve months ended December 31, 2024 and 2023 have been derived from the financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. (2) Some amounts in this statement may not add due to rounding. All percentages have been calculated using unrounded amounts. INTRA-CELLULAR THERAPIES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands except share and per share amounts) (Unaudited) December 31,2024 December 31,2023Assets Current assets: Cash and cash equivalents$306,948 $147,767 Investment securities, available-for-sale 694,118 350,174 Restricted cash 1,750 1,750 Accounts receivable, net 166,500 114,018 Inventory 26,283 11,647 Prepaid expenses and other current assets 111,765 42,443 Total current assets 1,307,364 667,799 Property and equipment, net 1,468 1,654 Right of use assets, net 13,428 12,928 Inventory, non-current 38,890 38,621 Other assets 5,762 7,293 Total assets$1,366,912 $728,295 Liabilities and stockholders’ equity Current liabilities: Accounts payable$26,074 $11,452 Accrued and other current liabilities 65,215 27,944 Accrued customer programs 75,408 53,173 Accrued employee benefits 34,774 27,364 Operating lease liabilities 4,233 3,612 Total current liabilities 205,704 123,545 Operating lease liabilities, non-current 12,748 13,326 Total liabilities 218,452 136,871 Stockholders’ equity: Common stock, $0.0001 par value: 175,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; 106,240,009 and 96,379,811 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively 11 10 Additional paid-in capital 2,840,094 2,208,470 Accumulated deficit (1,691,836) (1,617,160)Accumulated comprehensive income 191 104 Total stockholders’ equity 1,148,460 591,424 Total liabilities and stockholders’ equity$1,366,912 $728,295 The condensed consolidated balance sheets at December 31, 2024 and December 31, 2023 have been derived from the financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - ForexTV
SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a business update on Wednesday, March 26, 2025 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. About Perspective Therapeutics, Inc.Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are in Phase 1/2a imaging and therapy trials in the U.S. for the treatment of metastatic melanoma and neuroendocrine tumors, respectively. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at www.perspectivetherapeutics.com. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@perspectivetherapeutics.com Russo Partners, LLCNic JohnsonPerspectiveIR@russopr.com
Sunset Market Commentary - Action Forex
The European February composite PMI released today matched January’s 50.2 reading. That’s suggestive of near negligible output growth. Services was still the main driver but expanded at a slower pace (50.7 from 51.3). The 23-month long downturn in manufacturing eased slightly (47.3 from 46.6). France was to blame for the marginally weaker-than-expected outcome with a marked reduction in (services) business activity.
How Ferrari Became Europe's Most Valuable Car Maker
Ferrari’s meteoric rise to become Europe’s most valuable carmaker is not driven by production volume. While mass-market manufacturers like Volkswagen battle weak domestic demand and a costly transition to electric vehicles, Ferrari has mastered the art of scarcity, exclusivity, and brand mystique.